Zobraziť v EDS

Prognostic Factors and Effect Modifiers in Patients With Relapse or Refractory Diffuse Large B‐Cell Lymphoma After Two Lines of Therapy: A Systematic Literature and Expert Clinical Review

Uložené v:
Podrobná bibliografia
Názov: Prognostic Factors and Effect Modifiers in Patients With Relapse or Refractory Diffuse Large B‐Cell Lymphoma After Two Lines of Therapy: A Systematic Literature and Expert Clinical Review
Autori: Bastian von Tresckow, Pau Abrisqueta, Irene Zamanillo, Ángel Serna Pareja, Yuting Kuang, Jennifer Uyei, Mohsin Shah, Laura Walsh, Eileen Thorley, Krystal Cantos, Emaan Rashidi, Christian Hampp, Jessica J. Jalbert, Alexi N. Archambault, Yingxin Xu, Shivani Aggarwal, Srikanth Ambati, Hesham Mohamed, Qiufei Ma, Ana Jiménez‐Ubieto
Prispievatelia: Institut Català de la Salut, [von Tresckow B] Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer Consortium (DKTK Partner Site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany. [Abrisqueta P, Serna Pareja Á] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Zamanillo I] Hematology Department, University Hospital 12 de Octubre, Madrid, Spain. [Kuang Y, Uyei J] IQVIA Inc., Durham, North Carolina, USA, Vall d'Hebron Barcelona Hospital Campus
Zdroj: Eur J Haematol
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Informácie o vydavateľovi: Wiley, 2025.
Rok vydania: 2025
Predmety: DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, Cèl·lules B - Tumors - Tractament, Review, Quimioteràpia combinada, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso, Cèl·lules B - Tumors - Prognosi, Limfomes - Tractament, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico, Limfomes - Prognosi
Popis: ObjectivesThe objective of this systematic literature review (SLR) combined with expert clinical review was to identify and rank prognostic factors and effect measure modifiers (EMMs) systematically and comprehensively in patients with relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who initiate treatment after ≥ 2 prior lines of therapy (LoTs; 3L+ R/R DLBCL).MethodsWe performed an SLR of studies published between 2016 and 2021 and extracted study characteristics, prognostic factors, and EMMs. This was followed by clinical review and ranking of findings by subject matter experts using questionnaires, follow‐up interviews, and quantitative ranking.ResultsAcross 46 included studies, the SLR identified 36 prognostic factors significantly associated with ≥ 1 clinical outcome. Based on subject matter expert ranking of the SLR‐derived list, the five most important prognostic variables in descending order are: early chemo‐immunotherapy failure, Eastern Cooperative Oncology Group performance status, refractory to last LoT, number of prior LoTs, and double‐ or triple‐hit lymphoma.ConclusionsThis SLR and expert clinical review is the first to provide a comprehensive assessment of prognostic factors for 3L+ R/R DLBCL. No statistically significant EMMs were identified. This robust multi‐method approach can assist in selecting prognostic variables for comparative analyses between real‐world studies and clinical trials.
Druh dokumentu: Article
Other literature type
Popis súboru: application/pdf
Jazyk: English
ISSN: 1600-0609
0902-4441
DOI: 10.1111/ejh.14423
Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/40344463
http://hdl.handle.net/11351/13365
Rights: CC BY
Prístupové číslo: edsair.doi.dedup.....860c7049a9d595a9cd6c43deff8d9957
Databáza: OpenAIRE
Popis
Abstrakt:ObjectivesThe objective of this systematic literature review (SLR) combined with expert clinical review was to identify and rank prognostic factors and effect measure modifiers (EMMs) systematically and comprehensively in patients with relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who initiate treatment after ≥ 2 prior lines of therapy (LoTs; 3L+ R/R DLBCL).MethodsWe performed an SLR of studies published between 2016 and 2021 and extracted study characteristics, prognostic factors, and EMMs. This was followed by clinical review and ranking of findings by subject matter experts using questionnaires, follow‐up interviews, and quantitative ranking.ResultsAcross 46 included studies, the SLR identified 36 prognostic factors significantly associated with ≥ 1 clinical outcome. Based on subject matter expert ranking of the SLR‐derived list, the five most important prognostic variables in descending order are: early chemo‐immunotherapy failure, Eastern Cooperative Oncology Group performance status, refractory to last LoT, number of prior LoTs, and double‐ or triple‐hit lymphoma.ConclusionsThis SLR and expert clinical review is the first to provide a comprehensive assessment of prognostic factors for 3L+ R/R DLBCL. No statistically significant EMMs were identified. This robust multi‐method approach can assist in selecting prognostic variables for comparative analyses between real‐world studies and clinical trials.
ISSN:16000609
09024441
DOI:10.1111/ejh.14423